Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The innovation arm of Oxford University gains impact at board level with the addition of the former Minister for Public Health and Innovation and the former Chief Executive of Oxford Instruments.

Nicola Blackwood, the former Minister for Public Health and Innovation and MP for Oxford West and Abingdon, and Jonathan Flint, the former chief executive of the University’s first spinout company Oxford Instruments, have joined Oxford University Innovation’s (OUI) board as non-executive directors.

Nicola Blackwood was Chair of the Science & Technology Select Committee while in Parliament. There, she led inquiries into the science budget, big data, digital skills, space and satellites, and how UK science would be affected by the EU Referendum. As Minister for Public Health and Innovation, she held a portfolio that covered life sciences, mental health, global health security, and public health. Since leaving office, she has taken up a number of board roles, and acts as an advisor to innovation-focused companies.

Jonathan Flint is the President Elect of the Institute of Physics and the former Chief Executive Officer of Oxford Instruments. He has held managing director positions at BAE Systems, Vislink and EADS. At present, Jonathan holds board positions with Stadium plc, the Oxford Trust, and now OUI.

Find out more (Oxford University Innovation website)

Similar stories

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Immunology and AI drug discovery partnership agreed with Sensyne Health

The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.

Oxford overseas research facility expands to include diagnostics and genetics testing centre

The Oxford-Suzhou Centre for Advanced Research, known as OSCAR, has marked another significant milestone with the launch of OSCAR-Prenetics Innovation and Technology Centre for Advanced Molecular Diagnostics (the OSCAR-Prenetics ITC).

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

AIMday in Experimental Medicine in Psychiatry - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Experimental Medicine in Psychiatry.

Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.